Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-08-14 / Front Immunol 2019;10:1939Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-02-06 / Front Oncol 2019;9:50Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-01-01 / Klin Onkol 2019;32(1):70-74Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-12-05 / Front Immunol 2018;9:2759Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-10-01 / Front Immunol 2018;9:2265Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
/in Breast Cancer, Checkpoint-Inhibitors, Hyperthermia, International Publications /von 2018-09-07 / Integr Cancer Ther 2018 12;17(4):1297-1303Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2018-08-29 / CNS Oncol 2018 07;7(3):CNS22Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
/in Checkpoint-Inhibitors, International Publications /von 2018-08-22 / Expert Rev Vaccines 2018 08;17(8):697-705
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de